NMT Medical Announces Significant Changes To Its Clinical Trial Plans In The United States
CommentPost ArticleSave to My ArticlesList ArticlesRandom Article
Login is required to access that page
NMT MEDICAL ANNOUNCES SIGNIFICANT CHANGES TO ITS CLINICAL TRIAL PLANS IN THE UNITED STATESHeadache / Migraine News From Medical News Today, January 25, 2008
NMT Medical, Inc. (NASDAQ: NMTI) nnounced that the Company is closing down its patent foramen ovale (PFO)/migraine trial, MIST II, to focus its resources on its PFO/stroke opportunity. The move is expected to save the Company approximately $14 million over the next two to three years as it redistributes investments originally budgeted for MIST II. As a result of this decision, NMT has ceased patient enrollment in MIST II, which was being conducted at 20 centers in the United States.
Comments